A role for radiotherapy in the management of advanced medullary thyroid carcinoma: The Mayo Clinic experience

Jason A. Call, Jonathan S. Caudill, Bryan McIver, Robert L. Foote

Research output: Contribution to journalArticle

11 Scopus citations


Outcomes of external beam radiotherapy (EBRT) in advanced medullary thyroid carcinoma (MTC) are largely unknown. Retrospective review of data from patients with MTC, diagnosed from June 1, 1970, through December 31, 2007. Overall survival and locoregional tumor control rates were calculated. Seventeen patients had adjuvant or palliative EBRT delivered to 41 sites. Six patients initially had adjuvant EBRT (median, 60.80 Gy); none had relapse in the treated area. Five patients with locoregional recurrence after surgery were treated (median, 59.40 Gy), and durable disease control was achieved in 3. Twelve patients received palliative EBRT to 29 sites of metastatic disease (median, 30.00 Gy), which provided sustained symptom relief at 45% of sites. Five- and tenyear overall survival rates were 44% and 19%, respectively. Adjuvant EBRT may be most effective for prevention of locoregional recurrence. EBRT may provide sustained control of advanced, metastatic disease in select patients.

Original languageEnglish (US)
Pages (from-to)128-131
Number of pages4
JournalRare Tumors
Issue number3
StatePublished - Jul 12 2013



  • Medullary thyroid carcinoma
  • Radiotherapy

ASJC Scopus subject areas

  • Histology
  • Oncology

Cite this